Anderson Hoagland & Co. Purchases New Stake in Gilead Sciences, Inc. $GILD

Anderson Hoagland & Co. acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 28,967 shares of the biopharmaceutical company’s stock, valued at approximately $3,555,000.

Several other institutional investors and hedge funds also recently bought and sold shares of GILD. Norges Bank acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at about $2,150,268,000. Invesco Ltd. boosted its holdings in shares of Gilead Sciences by 12.0% during the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after purchasing an additional 1,618,453 shares during the period. Amundi grew its position in Gilead Sciences by 18.2% during the second quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock valued at $1,167,221,000 after purchasing an additional 1,614,355 shares in the last quarter. Legal & General Group Plc increased its stake in Gilead Sciences by 4.2% in the 3rd quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock valued at $1,133,376,000 after buying an additional 414,454 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in Gilead Sciences by 5.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock valued at $793,506,000 after buying an additional 400,002 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GILD. Oppenheimer lifted their target price on shares of Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. Morgan Stanley upped their price target on shares of Gilead Sciences from $150.00 to $171.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. BMO Capital Markets increased their price objective on Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, January 26th. Citigroup reissued a “buy” rating on shares of Gilead Sciences in a research report on Friday, March 6th. Finally, Royal Bank Of Canada upped their target price on Gilead Sciences from $103.00 to $118.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $157.62.

Insider Buying and Selling

In related news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at approximately $1,101,620. The trade was a 35.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the sale, the insider directly owned 120,288 shares of the company’s stock, valued at $18,577,278.72. The trade was a 18.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 309,280 shares of company stock valued at $44,068,850 over the last 90 days. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Stock Down 0.1%

GILD stock opened at $141.11 on Friday. The firm has a market cap of $175.18 billion, a PE ratio of 20.84, a PEG ratio of 1.85 and a beta of 0.37. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The company has a fifty day simple moving average of $142.36 and a 200 day simple moving average of $127.60. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the prior year, the business posted $1.90 earnings per share. The business’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is currently 48.45%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Pipeline boost — Assembly Biosciences licensed a helicase‑primase inhibitor program (including candidates ABI‑5366 and ABI‑1179) to Gilead after positive Phase 1b interim data, adding early‑stage herpes assets to Gilead’s antiviral franchise and expanding near‑term development options. This is a clear pipeline + inorganic expansion signal. Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
• Positive Sentiment: Analyst support — Multiple firms have raised targets or maintain buy ratings (Deutsche Bank, Jefferies, BofA, Needham), lifting consensus target above the current trade and providing institutional buying ammunition. This helps underpin the shares despite short‑term weakness.
• Positive Sentiment: Shareholder return signal — Gilead recently raised its quarterly dividend to $0.82 (ann. $3.28), reinforcing cash‑flow confidence and appeal to income investors. Dividend / SEC Filing
• Neutral Sentiment: Trending attention / coverage — Zacks and other outlets flagged GILD as a trending stock; that can increase intraday volume and volatility but doesn’t indicate fundamental change. Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
• Neutral Sentiment: Market‑flow signals — Unusual options activity and recent coverage pieces on valuation have attracted attention; these can amplify swings but are ambiguous for direction until large trades or analyst revisions follow. 2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch
• Negative Sentiment: Insider selling — Recent disclosed sales (including Johanna Mercier and a reported sale by the CFO) have been highlighted in filings and press summaries; insider sales can weigh on sentiment even when they’re routine or pre‑planned. Insider Sale – Johanna Mercier CFO SEC Filing

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.